{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-026771","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-08-10T20:07:12+00:00","discovered_at":"2026-08-10T20:08:00.259352+00:00","generated_at":"2026-08-10T20:08:17.801978+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CervoMed Q2 net loss $6.6M; neflamapimod data supports Phase 3 DLB plan","bullets":["Net loss $6.6M vs $6.3M YoY; cash $24.9M at June 30, 2026, runway to Q3 2027.","Grant revenue zero vs $1.8M; R&D $4.3M vs $5.1M; G&A $2.4M vs $3.3M.","AAIC data: CDR-SB improvement 0.70 (p=0.054) in pure DLB; basal forebrain atrophy slowed (p=0.028).","Neflamapimod awarded UK ILAP Innovation Passport; company pursuing partnership for Phase 3 DLB trial.","Raised ~$20.5M gross in June equity financings; ended RAS enrollment, completed nfvPPA enrollment."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-026771","json":"https://secwatch.observer/filing/0001437749-26-026771.json","markdown":"https://secwatch.observer/filing/0001437749-26-026771.md","text":"https://secwatch.observer/filing/0001437749-26-026771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/0001437749-26-026771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/crvo20260810_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:08:17.801978+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}